Pyrazinamide (PZA) is widely used in combination with other drugs in chemotherapy for tuberculosis (TB). However, the dose-related liver injury is the main adverse effect of PZA and its metabolite (pyrazinoic acid; PA). Silibinin is the main flavonoid extracted from milk thistle (Silybum marianum), and it displays hepatoprotective properties. This study investigates the pharmacokinetics of PZA and PA, and their interaction with silibinin in rats. The parallel study design was divided into six groups:
Introduction
immobilized in a stereotaxic frame (David Kopf Instruments, Tujunga, CA, USA).
The skull was surgically exposed, and a hole was trephined into the skull based on stereotaxic coordinates. The brain microdialysis probe was placed into the right striatum (0.2 mm anterior to bregma, 3.2 mm lateral to midline and 7.5 mm lower to tip). The brain microdialysis probe was perfused with Ringer's solution at a flow-rate of 2.4 µl min -1 .
Drug administration
Animals were divided into six groups, after a 2 h post-surgical stabilization period following the implantation of microdialysis probes, PZA (50 mg kg -1 , i.v.) or PA (30 mg kg -1 , i.v.) was administered via the femoral vein as the control groups of PZA alone and PA alone groups, respectively. The following four treated groups were PZA + long-term silibinin exposure, PA + long-term silibinin exposure, PZA + concomitant short-term silibinin exposure, and PA + concomitant short-term silibinin exposure group.
For the PZA + long-term silibinin exposure group and PA + long-term silibinin exposure group, silibinin 100 mg kg -1 was given orally for three consecutive days and on the fourth day, PZA (50 mg kg 
Recovery of microdialysate
It is possible that the analytes adhere to the microdialysis apparatus. Besides, matrix effect and cross over could disturb the microdialysis and analytical systems. To avoid these interferences, an in vivo recovery was performed by the following steps. The blood, brain and bile microdialysis probes were inserted into the rat jugular vein, brain striatum and bile duct under anesthesia with urethane 1 g ml -1 and chloralose 0.1 g ml -1
. Ringer's solutions containing PA 6, 10 and 20 µg ml -1
, and PZA 10, 30 and 60 µg ml -1 were passed through the microdialysis probe into rat bile and brain. In addition, ACD solutions containing PA 6, 10 and 20 µg ml -1 , and PZA 10, 30 and 60 µg ml -1 were passed through the microdialysis probe into rat blood. These were all done by individual experiment at a constant flow rate of 2.4 µl min -1 using an infusion pump (CMA 100). Following a stabilization period of 2 h post probe implantation, the perfusate (C perf ) and dialysate (C dial ) concentrations of PZA and PA were determined by HPLC. The in vivo relative recovery (R dial ) of PZA and PA across the microdialysis probe was calculated by the following equation: R dial = (C perf -C dial )/C perf .
Pharmacokinetic application
The protein-unbound concentrations (C u ) of analytes in the extracellular fluid were corrected from the concentration in dialysate (C m ) as follows: C u = C m /R dial .
Pharmacokinetic calculations were performed on each individual set of data using the pharmacokinetic software WinNonlin Standard Edition Version 1.1 (Pharsight Corp., This article has not been copyedited and formatted. The final version may differ from this version. Mountain View, CA, USA) by the noncompartmental method.
The areas under the concentration-time curves (AUC) were calculated according to the log linear trapezoidal method. The clearances (Cl) were calculated as follows: Cl = dose/AUC. The blood to tissue distributions were calculated as follows:
AUC tissue /AUC blood (Lin et al., 1982) . All data are presented as mean ± standard error mean.
Statistics
The results were represented as mean + standard error of the mean. The statistical analysis was performed with SPSS version 10.0 (SPSS Inc. Chicago, IL, USA).
One-way ANOVA was followed by a Dunnett's post hoc test comparison among PZA alone, PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure groups, and PA alone, PA + long-term silibinin exposure and PA + concomitant short-term silibinin exposure groups. All statistical tests were performed at the two-sided 5% level of significance.
Results

Chromatograms in blood, brain and bile
The characteristics of analytes are hydrophilic compounds and the mobile phase without contain organic solvent for the reversed phase column. In order to avoid the contamination of endogenous substance or analytes in the column, the column was washed with methanol (50%) for 1 hr after experimental day. Following the above method, protein-unbound PZA was found in the dialysates of blood, brain and bile, Figure 1 . Separation of PZA and PA from endogenous substances in the blood dialysate was achieved in an optimal mobile phase containing 10 mM monosodium phosphate -triethylamine (100:0.1, v/v, pH 3 adjusted by orthophosphoric acid). The retention times of PA and PZA were 7 and 12 min, respectively. Figure 1A shows a calibration sample of PZA (10 µg ml -1 ) and PA (10 µg ml -1 ), and Figure 1B shows the chromatogram of a blank blood dialysate.
None of the observed peaks interfered with the analyte within the retention times of the analytes. Figure 1C shows the chromatogram of a blood dialysate sample containing PA (0.45 µg ml -1 ) and PZA (19.22 µg ml -1 ) collected from the rat blood microdialysate at 90 min after PZA administration (50 mg kg -1 , i.v.). Figure 2A shows a calibration sample of PA (5 µg ml -1 ) and PZA (5 µg ml -1
), and Figure 2B shows the chromatogram of a blank brain dialysate. Figure 2C shows the chromatogram of a brain dialysate sample containing PZA (4.26 µg ml -1 ) collected from the rat brain microdialysate 40 min post PZA administration (50 mg kg -1 , i.v.).
PA in brain dialysate was not detected in this analytical system. Figure 3A shows a calibration sample of standard PA (10 µg ml -1
) and PZA (10 µg ml -1 ). Figure 3B shows the chromatogram of a blank bile dialysate sample obtained from bile duct microdialysis probe before the drug administration. Figure 3C shows the chromatogram of bile dialysate sample containing PA (1.07 µg ml 
Method validation
The calibration curves of PZA and PA were obtained prior to the LC analysis of dialysates over a concentration range of 0.1-100 µg ml -1 (r 2 > 0.995). The concentrations of PZA and PA were linearly related to the peak areas of the chromatogram. The intra-assay and inter-assay accuracy and precision were thus found to be acceptable for the analysis of a dialysis sample in support of pharmacokinetic studies (Bressolle et al., 1996) . This method is sufficiently sensitive to allow for the measurement of PA in rat blood, bile and PZA in rat blood, brain and bile for pharmacokinetic study.
In vivo recoveries of PA and PZA
Average in vivo recoveries of PZA were 33.4 + 1.7 %, 15.4 + 0.9 % and 80.3 + 1.6 % for blood, brain and bile, respectively. Average in vivo recoveries of PA were 36.0 + 1.8 %, 16.3 + 0.8 % and 81.9 + 1.5 % for blood, brain and bile, respectively. The data indicated that no significant difference in recovery values for the same region was observed after the addition of PZA or PA to the perfusate. The recoveries from the microdialysis probes in rat blood, brain and bile were independent of the concentration required for these experiments. The surface area of the dialysis membrane is one of the major factors for the recovery. Due to the small brain regional area, the dialysis membrane of microdialysis probe is much smaller than the probes for blood and bile. This may lead to the brain recovery smaller than the blood and bile.
This article has not been copyedited and formatted. The final version may differ from this version. ), followed by a slow elimination phase.
For the groups of PZA alone, PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure, PZA concentrations in the blood were not significantly altered. The metabolite PA concentrations in blood were gradually increased after PZA administration up to a plateau during 1-2 h (Fig. 5) . The blood AUCs of PZA in both PZA + long-term silibinin exposure group and PZA + concomitant short-term silibinin exposure groups were 18200 + 4500 and 20200 + 2100 min µg ml -1 , which was not significantly different from the PZA alone group (19300 + 3800). However, the AUCs of metabolite PA in both PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure groups were 809 + 69 and 568 + 23 min µg ml -1 , which were significantly higher than the PZA alone group (212 + 22).
After long-term silibinin exposure or concomitant short-term silibinin exposure prior to PZA administration, PZA concentrations in the brain were not significantly altered (Fig. 6 ). The brain AUCs of PZA in the groups of PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure were 6900 + 710 and 7800 + This article has not been copyedited and formatted. The final version may differ from this version. ).
After long-term silibinin exposure or concomitant short-term silibinin exposure prior to PZA administration, the PZA concentrations in bile were not significantly altered (Fig. 7) . The bile AUCs of PZA in both groups of PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure were 14900 + 2300 and 23900 + 3600 min µg ml -1 , which were not significantly different from the PZA alone group (20500 + 4200). The metabolite PA concentrations in bile were gradually increased after PZA administration up to a plateau around 1 h (Fig. 8) . The AUCs of the metabolite PA in both groups PZA + long-term silibinin exposure and PZA + concomitant short-term silibinin exposure were 649 + 29 and 407 + 76 min µg ml -1 , respectively, which were not significantly different from the PZA alone group (527+ 28 min µg ml -1 ).
The hepatobiliary distribution of PZA was defined as the bile-to-blood distribution (k value), which was calculated by the AUC ratio in bile-to-blood (k = AUC bile /AUC blood ) 
Interaction of silibinin and protein-unbound PA in blood, and bile
Mean PA concentrations versus time profiles in blood, and bile with the PA alone, PA + long-term silibinin exposure and PA + concomitant short-term silibinin exposure groups are presented in Figs. 9-10 and the pharmacokinetic data is presented in Table   3 . The pharmacokinetic curves of the PA alone group show that the disposition of PA in rat bile exhibited a peak concentration at 20 min of PA administration (30 mg kg -1 ),
followed by a slow elimination phase.
After long-term silibinin exposure or concomitant short-term silibinin exposure prior to PA administration, PA concentrations in the blood were markedly increased (Fig. 9) .
The blood AUC of PA in the groups of PA + long-term silibinin exposure and PA + concomitant short-term silibinin exposure groups were 3140 + 300 and 3730 + 380 min µg ml -1 , which was significantly increased from the PA alone group (892 + 140) ( Table 3 ).
The PA concentrations in the bile quickly reached a maximum level within 20 min and then gradually decreased (Fig. 10) . After concomitant short-term silibinin exposure prior to PA administration, PA concentrations in the bile were not significantly altered, but after long-term silibinin exposure, PA concentrations in the bile were significantly decreased. The bile AUC of PA in the PA + long-term silibinin exposure groups were 2830 + 270, which was significantly increased from the PA alone group. The bile AUC of PA in the PA + concomitant short-term silibinin This article has not been copyedited and formatted. The final version may differ from this version. ).
The bile-to-blood excretion PA in the groups of PA + long-term silibinin exposure and PA + concomitant short-term silibinin exposure were 0.96 + 0.16 and 0.92 + 0.08, respectively, which were significantly decreased from the PA alone group (3.74 + 0.41).
Discussion
This study performed in rats demonstrates that the mean concentration of PZA in the brain increased during the first 10 min, reaching a peak concentration (Cmax: 23.68 + 3.68 µg ml -1 ) at 20-30 min (Table 1) 
